Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.52 SEK | -3.95% | +2.48% | +6.86% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.86% | 54.24M | |
+10.08% | 9.12B | |
-17.63% | 4.8B | |
+0.73% | 3.8B | |
+16.55% | 3.72B | |
+27.76% | 2.58B | |
-26.11% | 2.36B | |
-30.09% | 2.11B | |
+7.15% | 1.86B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Sweden's Orexo Wins First Patent for Nasal Adrenaline Rescue Medication in Europe